Medicine Name: Andexxa/Ondexxya
Generic Name: Andexanet alfa
Dosage Form & Strength: Injection: 200 mg lyophilized powder in single-use vials
Manufactured By: by Alexion Pharmaceuticals, Inc/Portola Pharmaceuticals UK Ltd.
Andexanet alfa (trade name U.S.: Andexxa, EU: Ondexxya) is a recombinant modified human factor Xa (FXa) protein used for stopping life-threatening or uncontrolled bleeding in adults who are taking a direct factor Xa (FXa) inhibitor or anti-clotting medicines (blood thinners) named apixaban or rivaroxaban.
Recommended Dosage: Dosage of Andexanet alfa should be administered intravenously, through a 0.2 or 0.22-micron in-line polyethersulfone or low protein-binding filter. The recommended dosage of Andexanet alfa is 400 mg administered as an initial intravenous (IV) bolus, with a target rate of 30 mg/min, followed by continuous infusion of 4 mg/min for up to 120 minutes (low dose), or 800 mg administered as an initial intravenous (IV) bolus, with a target rate of 30 mg/min, followed by continuous infusion of 8 mg/min for up to 120 minutes (high dose).
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.